[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"diabetes-mellitus-type-2\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:diabetes-mellitus-type-2":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,241,0,25,[9,60,85,108,135,163,194,216,241,261,283,303,322,344,375,397,422,445,470,494,517,540,566,593,626],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":45,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100637347","phase-3-a-study-of-orforglipron-ly3502970-in-participants-with-type-2-diabetes-who-observe-ramadan-fasting-100637347",false,"NCT07613307","A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting","A Phase 3b, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Efficacy and Safety of Orforglipron in Adult Participants With Type 2 Diabetes Who Observe Ramadan Fasting (ACHIEVE-RAM)","ACHIEVE-RAM","Inclusion Criteria:\n\n* Have a clinical diagnosis of T2D based on the World Health Organization (WHO) classification or other locally applicable diagnostic standards.\n* Have an HbA1c value of at least 7.0% (53 millimoles per mole (mmol\u002Fmol)) to less than 9.5% (91 mmol\u002Fmol) at screening.\n* Intend to be compliant with the fast during the Ramadan period.\n* Have had stable body weight self-reported change of 5 kilograms (kg) or lower during the 90 days prior to screening.\n* Have body mass index (BMI) of 25 kilograms per meter square (kg\u002Fm2) or higher at screening.\n\nExclusion Criteria:\n\n* Have any form of diabetes other than T2D, including type 1 diabetes (T1D), gestational diabetes, latent autoimmune diabetes, maturity-onset diabetes of the young, and medication-induced diabetes\n* Have a family (first-degree relative) or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.\n* Have a history of chronic or acute pancreatitis any time prior to screening\n* Have evidence of a significant, uncontrolled endocrine abnormality, for example, thyrotoxic or adrenal crises, in the opinion of the investigator\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years.\n* Have a history of cholecystectomy (surgically removed gallbladder)\n* Have New York Heart Association Functional Classification IV congestive heart-failure.","ALL","18 Years","65 Years",{"count":22,"type":23},130,"ESTIMATED","INTERVENTIONAL",[26],"PHASE3","The purpose of this study is to test the efficacy and safety of orforglipron in participants with T2D (type 2 diabetes) who participate in fasting during Ramadan. For each participant, the study will last up to 48 weeks with a minimum of 7 in clinic visits and 4 virtual visits.",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44],"Diabetes Mellitus, Type 2","Diabetes Melletus","Glucose Metabolism Disorders","Metabolic Disorders","Nutritional and Metabolic Diseases","Endocrine System Diseases","Feeding Behavior","Behavior","Fasting","Glucagon-Like Peptide-1 Receptor","Glucagon-Like Peptide Receptors","Receptors, G-Protein-Coupled","Receptors, Cell Surface","Membrane Proteins","Proteins","Receptors, Peptide",[46,37],"Ramadan","RECRUITING","2026-08-20",{"date":50,"type":51},"2026-08-21","ACTUAL",{"date":53,"type":51},"2026-07-15",{"date":55,"type":23},"2027-05",{"name":57,"class":58},"Eli Lilly and Company","INDUSTRY",40,{"id":61,"slug":62,"hasResults":12,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":83,"locationsCount":84},"100609513","phase-2-a-study-of-macupatide-ly3532226-and-eloralintide-ly3841136-alone-or-in-combination-in-adults-with-obesity-or-overweight-and-with-type-2-diabetes-100609513","NCT07215559","A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes","A Phase 2, Parallel-Group, Double-Blind, Placebo-Controlled Study to Investigate Weight Reduction With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight and With Type 2 Diabetes","Inclusion Criteria:\n\n* Have type 2 diabetes\n* Have an HbA1c ≥7.5% to ≤10.5% at screening\n* Have been treated with any of the following, alone or in combination, for at least 3 months prior to screening\n\n  * Diet and exercise\n  * Stable dose of metformin\n  * Sodium-glucose cotransporter-2 (SGLT2) inhibitor\n* Have had a stable body weight (\\\u003C5% body weight gain and\u002For loss) for the 3 months prior to screening\n* Have a BMI of 27 or greater at screening\n\nExclusion Criteria:\n\n* Have any form of diabetes other than type 2 diabetes\n* Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed \\>1 year prior to screening\n* Have any of the following cardiovascular conditions within 3 months prior to screening:\n\n  * acute myocardial infarction\n  * cerebrovascular accident (stroke)\n  * unstable angina, or\n  * hospitalization due to congestive heart failure\n* Have a history of an active or untreated malignancy or are in remission from a clinically significant malignancy for less than 5 years, exceptions include\n\n  * basal or squamous cell skin cancer\n  * in situ carcinomas of the cervix, or\n  * in situ prostate cancer\n* Have been prescribed any of the following receptor agonists (RA) or their combination for any indication within the last 6 months:\n\n  * amylin RA\n  * dual amylin and calcitonin RA\n  * glucagon-like peptide-1 receptor (GLP-1) RA\n  * glucose-dependent insulinotropic peptide (GIP)\u002FGLP-1 RA\n  * GLP-1\u002Fglucagon (GCG) RAs, or\n  * GIP\u002FGLP-1\u002FGCG RAs\n* Have used excluded antihyperglycemic medications within 3 months prior to screening (including, but not limited to, sulfonylureas, dipeptidyl peptidase-4 inhibitors, alpha-glucosidase inhibitors, thiazolidinediones, and meglitinides\n* Have used insulin for diabetic control within the prior year (short term use in certain situations allowed","75 Years",{"count":69,"type":23},200,[71],"PHASE2","The purpose of this study is to investigate weight reduction with macupatide and eloralintide, alone or in combination, in adult participants with obesity or overweight and with type 2 diabetes. Participation in the study will last about 48 weeks.",[74,75,29],"Obesity","Overweight",[77,78],"GIP","Amylin",{"date":50,"type":51},{"date":81,"type":51},"2025-10-16",{"date":55,"type":23},{"name":57,"class":58},42,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":24,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100597898","phase-3-easi-protkt---a-study-to-test-vicadrostat-bi-690517-taken-together-with-empagliflozin-in-people-with-type-2-diabetes-high-blood-pressure-and-cardiovascular-disease-100597898","NCT07064473","EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease","EASi-PROTKT™ - A Phase III Double-blind, Randomised, Parallel-group Superiority Trial to Evaluate Efficacy and Safety of the Combined Use of Oral Vicadrostat (BI 690517) and Empagliflozin Compared With Placebo and Empagliflozin in Participants With Type 2 Diabetes, Hypertension and Established Cardiovascular Disease","Inclusion Criteria :\n\n* At least 18 years old at time of consent\n* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial\n* Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2).\n* Participants with medical history of hypertension and on active pharmacological treatment\n* Participants with medical history of type 2 diabetes mellitus (T2DM) and on active pharmacological treatment\n* Established cardiovascular (CV) disease and on active pharmacological treatment\n* At least one additional risk factor for developing heart failure (HF)\n\nExclusion Criteria:\n\n* History of HF or hospitalization for HF or treatment of HF\n* Atrial fibrillation or Atrial flutter with a resting heart rate \\>110 beats per minute (bpm) documented by echocardiogram (ECG) at Visit 1 (screening)\n* Advanced untreated conduction disease or untreated clinically relevant ventricular arrhythmia at Visit 1 (screening)\n* Treatment with an Mineralocorticoid receptor antagonist (MRA)\n* Treatment with amiloride or other potassium-sparing diuretic\n* Receiving the following treatments at Visit 1 (screening) or requiring such treatment before Visit 2 (randomisation), or planned during the trial:\n\n  * A direct renin inhibitor (e.g. aliskiren)\n  * More than one Angiotensin-converting enzyme inhibitor (ACEi) and\u002For Angiotensin receptor blocker (ARB) (including Angiotensin receptor-neprilysin inhibitor (ARNi)) used simultaneously\n  * Other aldosterone synthase inhibitors (e.g. baxdrostat)\n  * Systemic mineralocorticoid replacement therapy (e.g. fludrocortisone) Further exclusion criteria apply.",{"count":93,"type":23},11800,[26],"This study is open to adults with type 2 diabetes, high blood pressure, and cardiovascular disease. People can join the study if they have these conditions and do not have a history of heart failure. The purpose of this study is to find out if a medicine called vicadrostat, when taken with empagliflozin, helps reduce cardiovascular risk in people with these conditions. The study will compare this combination to a placebo version of vicadrostat with empagliflozin.\n\nParticipants are put into 2 groups randomly, which means by chance. One group takes vicadrostat and empagliflozin tablets, and the other group takes placebo tablets with empagliflozin. Placebo tablets look like vicadrostat tablets but do not contain any medicine.\n\nParticipants take a tablet once per day for 2 and a half years and up to 4 years and 3 months. All participants also continue their medication for type 2 diabetes, high blood pressure, and cardiovascular disease. Participants have an equal chance of receiving the study medicine or placebo.\n\nParticipants are in the study for up to 4 years and 3 months. During this time, they visit the study site regularly. During these visits, doctors collect information about participants' health and take blood samples. The doctors document when participants experience cardiovascular events. The doctors also regularly check participants' health and take note of any unwanted effects.",[29,97,98],"Hypertension","Cardiovascular Diseases","2026-08-19",{"date":48,"type":51},{"date":102,"type":51},"2025-07-22",{"date":104,"type":23},"2029-12-21",{"name":106,"class":58},"Boehringer Ingelheim",1147,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":18,"minAge":117,"maxAge":4,"enrollmentInfo":118,"targetDuration":4,"studyType":24,"phases":120,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100524721","a-randomized-comparison-of-stage-based-care-versus-risk-factor-based-care-for-prevention-of-cardiovascular-events-100524721","NCT06112418","A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events","A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events","TRANSFORM","Inclusion Criteria:\n\n1. Provided electronic or written informed consent\n2. Men \\> 55, women \\> 65 years of age\n3. Type 2 diabetes mellitus requiring pharmacologic therapy, prediabetes (most recent HbA1c 5.7 to 6.4% and\u002For fasting glucose 100-125 mg\u002FdL \\[5.6-6.9 mmol\u002FL\\]) and\u002For metabolic syndrome. Metabolic syndrome is defined as \\> 3 of the following criteria (International Diabetes Federation 2006):\n\n   * Body mass index ≥ 27 kg\u002Fm2 or abnormal waist circumference defined as ≥ 80 cm (31.5 inches) for women, ≥ 94 cm (37 inches) for men; for South and East Asian men (e.g., Asian Indian, Chinese, Japanese) ≥ 90 cm (35.4 inches)\n   * Fasting triglycerides ≥ 150 mg\u002FdL (1.7 mmol\u002FL) or treated hypertriglyceridemia\n   * HDL-cholesterol (HDL-C) \\\u003C 40 mg\u002FdL (1.03 mmol\u002FL) in men, \\\u003C50 mg\u002FdL (1.29 mmol\u002FL) in women or treatment for this lipid abnormality\n   * Systolic blood pressure (BP) ≥ 130 and\u002For diastolic BP≥ 85 mm Hg and\u002For treated hypertension\n   * Fasting blood glucose ≥ 100 mg\u002FdL (5.6 mmol\u002FL) or HbA1c ≥ 5.7%\n4. Have a device (e.g., smartphone, tablet, computer) for communication with the central cardiologist-led team managing drug treatment for the personalized care group\n\nExclusion Criteria:\n\n1. History of symptomatic CVD defined as prior MI, exertional or unstable angina, ischemic stroke, claudication, arterial revascularization for atherosclerosis or other CVD being actively managed by a cardiologist, e.g. atrial fibrillation, heart failure\n2. Planned arterial revascularization\n3. Inability to complete screening CCTA or any condition that would increase the risk associated with CCTA or increase likelihood of uninterpretable scan including:\n\n   1. eGFR \\\u003C 60 mL\u002Fmin\u002F1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) or Modification of Diet in Renal Disease (MDRD) equation (www.kidney.org\u002Fprofessionals\u002Fkdoqi\u002Fgfr\\_calculator)\n   2. Allergy to iodinated contrast or history of contrast-induced nephropathy (including adverse reaction to contrast at screening CCTA) or screening laboratory values consistent with untreated hyperthyroidism. Participants with elevated thyroid-stimulating hormone (TSH) may be enrolled but should be referred to their physician for evaluation for treatment.\n   3. Thyroid cancer in the previous five (5) years or planned radioactive iodine treatment\n   4. Weight \\> 300 lbs. (136 kg) or above manufacturer-recommended limit for scanner and table at the site\n   5. Inability to hold breath for \\> 10 seconds\n   6. Active arrhythmia (atrial fibrillation, atrial flutter, frequent premature atrial, or ventricular contractions) with poorly controlled rate (i.e., \\> 80 beats per minute at screening or prior to CCTA)\n   7. Contraindication to dosing with beta blocker or nitroglycerin on day of screening CCTA\n   8. Any other factor that, in the opinion of the investigator, would increase participant risk or increase the chance of an uninterpretable CCTA\n4. Unsuitable as a trial participant in the opinion of the investigator for reasons including significant left main stenosis (e.g. ≥ 70%; site will be notified by Cleerly), other health condition with life expectancy \\\u003C 3 years or being at risk of poor compliance with study procedures (e.g., active substance abuse or untreated mental illness that, in the opinion of the investigator, is likely to adversely affect adherence or retention)",true,"55 Years",{"count":119,"type":23},7500,[121],"NA","TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.",[29,124,125],"PreDiabetes","Metabolic Syndrome","2026-08-18",{"date":99,"type":51},{"date":129,"type":51},"2024-03-06",{"date":131,"type":23},"2029-03-05",{"name":133,"class":58},"Cleerly, Inc.",125,{"id":136,"slug":137,"hasResults":12,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":145,"conditions":146,"keywords":149,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":4},"100648270","evaluation-of-the-risk-of-heart-failure-in-patients-with-chronic-kidney-disease-and-type-2-diabetes-mellitus-100648270","NCT07719621","Evaluation of the Risk of Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus","Implication of Albuminuria Reduction and Other Cardiorenal Effects on The Risk of Heart Failure in Patients With CKD and T2D","Inclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Patients with chronic kidney disease (eGFR 30-90 ml\u002Fmin\u002F1.73 m²)\n* Persistent albuminuria (UACR 100-5000 mg\u002Fg)\n* Type 2 diabetes mellitus (T2D) under stable blockade of the renin-angiotensin system (ACEi\u002FARB)\n\nExclusion Criteria: The same characteristics of the reference population: CONFIDENCE trial (NCT05254002). In brief:\n\n* Participants with type 1 diabetes (T1D).\n* Participant with hepatic insufficiency classified as Child-Pugh C.\n* Participants currently treated or who were treated with Finerenone (Kerendia©) within 8 weeks prior to the screening visit.",{"count":143,"type":23},50000,"OBSERVATIONAL","The goal of this study, performed entirely with computer programs, is to learn if using a combination of two drugs works better than using one alone, in the treatment of people with chronic kidney disease and type 2 diabetes mellitus.\n\nThe main questions it aims to answer are:\n\n* How many events of heart failure, heart failure hospitalizations, and cardiovascular death happen in each group?\n* How do serious kidney problems progress in each of the groups?\n\nResearchers will compare reference therapy (finerenone) with a combination of finerenone and empagliflozin.\n\nThere will not be human participants in this study. With the help of artificial intelligence, researchers will recreate a large population of people with chronic kidney disease and type 2 diabetes mellitus. Data on their disease, treatment, and laboratory parameters will be based on and simulated using real data from previous clinical trials conducted with real participants.",[147,148],"CKD - Chronic Kidney Disease","Diabetes Mellitus Type 2",[150,148,151,152],"Chronic Kidney Disease","finerenone","empagliflozin","NOT_YET_RECRUITING","2026-08-17",{"date":99,"type":51},{"date":157,"type":23},"2026-09",{"date":159,"type":23},"2026-11",{"name":161,"class":162},"Aeterna Medical Solutions SL","OTHER",{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":18,"minAge":171,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":24,"phases":175,"briefSummary":176,"conditions":177,"keywords":178,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":188,"startDateStruct":189,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100643997","phase-3-a-study-of-orforglipron-ly3502970-compared-with-dulaglutide-in-pediatric-participants-with-type-2-diabetes-100643997","NCT07668336","A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes","A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes","ACHIEVE-PEDS","Inclusion Criteria:\n\n* Have type 2 diabetes treated with diet and exercise and metformin and\u002For basal insulin\n* Have HbA1c \\> 6.5% to ≤ 11.0% at screening\n* Have a body weight ≥50 kilograms (kg) (110 pounds) and a body mass index (BMI) of \\>85th percentile\n\nExclusion Criteria:\n\n* Have type 1 diabetes\n* After the type 2 diabetes diagnosis, have a history of diabetic ketoacidosis or hyperosmolar syndrome\n* Have had at least one episode of severe hypoglycemia and\u002For at least one episode of hypoglycemic unawareness within the last 6 months before screening\n* Have a history of pancreatitis or gallbladder disease\n* Have a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2)\n* Have received treatment with any glucose-lowering agent(s) other than metformin, basal insulin, or (SGLT2) inhibitors within 90 days prior to screening\n* Have been treated with prescription drugs or over-the-counter medications that promote weight loss within 90 days prior to screening","10 Years","17 Years",{"count":174,"type":23},170,[26],"This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them.\n\nParticipation in the study will last about 61 weeks.",[29],[179,180,181,182,183,184,185,186,187],"Pediatric trial","GLP-1 receptor agonist","Oral GLP-1","Small molecule GLP-1","Youth-onset type 2 diabetes","Glycemic control","Continuous glucose monitoring","Non-inferior","Active-controlled",{"date":99,"type":51},{"date":157,"type":23},{"date":191,"type":23},"2030-03",{"name":57,"class":58},71,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":12,"sex":18,"minAge":20,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":24,"phases":202,"briefSummary":203,"conditions":204,"keywords":206,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":209,"startDateStruct":210,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100629415","diabetes-multimorbidity-typology-trajectory-and-feasibility-of-an-audio-diary-mobile-application-to-support-self-management-100629415","NCT07474376","Diabetes Multimorbidity Typology, Trajectory, and Feasibility of an Audio Diary Mobile Application to Support Self-management","Inclusion Criteria:\n\n* Diagnosed type 1 or 2 diabetes and at least one comorbidity (eg, obesity, HIV, heart failure, polycystic ovary syndrome, obstructive sleep apnea, and prediabetes with and without hypertension)\n* Being able to fill in the Redcap surveys, and install and use the audio diary app.\n\nExclusion Criteria:\n\n•Those who cannot use (e.g., no mobile phone, incompatible system), read, type, speak, or understand English in Redcap or the audio diary mobile app.",{"count":201,"type":23},30,[121],"The goal of this clinical trial is to evaluate whether an audio diary mobile application (Fabla-diabetesMM) is feasible to use and may support self-management in older adults with type 1 or 2 diabetes and multimorbidity.\n\nThe main questions it aims to answer are:\n\n* Is it feasible to adapt and implement the Fabla-diabetesMM audio diary mobile app among 30 older adults with diabetes and multimorbidity\n* Does the use of the audio diary mobile app affect self-management outcomes",[29,205],"Diabetes Mellitus, Type 1",[207],"Diabetes self management","2026-08-14",{"date":154,"type":51},{"date":157,"type":23},{"date":212,"type":23},"2027-03",{"name":214,"class":162},"Emory University",1,{"id":217,"slug":218,"hasResults":12,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":12,"sex":18,"minAge":224,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":227,"conditions":228,"keywords":229,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":208,"lastUpdatePostDateStruct":233,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100619444","screening-for-change-early-risk-detection-and-integrated-prevention-for-diabetes-and-cardiovascular-diseases-in-the-marche-region-100619444","NCT07344701","\"Screening for Change: Early Risk Detection and Integrated Prevention for Diabetes and Cardiovascular Diseases in the Marche Region\"","Early Risk Detection of Type 2 Diabetes and Cardiovascular Diseases: an Italian Cohort Study","JAC_AST","Inclusion Criteria:\n\n* Citizens resident in Ascoli Piceno province\n* People turning 50 in 2026\n* Capacity to consent\n* Fulfilling and signing the informed consent related to the participation to the study.\n\nExclusion Criteria:\n\n* a concomitant diagnosis of DM and a previous CVD major event (one or more between Myocardial infarction, Haemorrhagic and\u002For ischaemic stroke, Revascularization interventions, as percutaneous coronary intervention\u002Fcoronary artery bypass graft)\n* Failure to meet the inclusion criteria\n* Lack of written informed consent.","50 Years",{"count":226,"type":23},2951,"This study aims to test the feasibility of a new systematic screening program to allow the early detection of individuals aged 50 years at risk of type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs) in the resident in the province of Ascoli Piceno and without previous diagnosis, using the CUORE and FINDRISDC tools developed in the Project.\n\nThe intervention will be conducted at the premises of the Prevention Department in Ascoli Piceno and San Benedetto del Tronto, within the Local Health Authority of Ascoli Piceno (Marche Region, Italy), throughout 2026.\n\nEligible individuals will be invited, based on recruitment criteria, to the screening via a letter containing study information and participation instructions. Those willing to participate will book the appointment to undergo the screening in one of the two premises of the Prevention Department involved in the study (namely, San Benedetto del Tronto and Ascoli Piceno), through the regional reservation system (CUP). On the scheduled date, participants will visit the Prevention Department, where healthcare professionals (HCPs) will explain the study, obtain the informed consent, and collect data related to the CUORE and\u002For FINDRISC questionnaires, as well as sociodemographic information. The calculated scores will determine the 10-year risks of T2DM and major CVD events. Based on these risks, participants will be provided with tailored suggested pathways. A summary letter outlining these pathways will be delivered, and, in case of consent, results will be added to the participants' Electronic Health Record. Follow-up calls will be scheduled at 3 (T1) and 6 (T2) months to assess adherence to the suggested pathway (e.g., visit the General Practitioner (GP), lifestyle counselling) through a phone call.",[98,148],[230,231,232,148,98],"Diagnostic Screening Program","Delivering of healthcare, integrated","risk factors",{"date":154,"type":51},{"date":235,"type":51},"2026-04-09",{"date":237,"type":23},"2026-12-31",{"name":239,"class":162},"Marche Region Regional Health Agency",2,{"id":242,"slug":243,"hasResults":12,"nctId":244,"briefTitle":245,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":215},"100651977","mazdutide-for-remission-of-type-2-diabetes-multicentre-double-blind-randomised-placebo-controlled-trial-100651977","NCT07767552","Mazdutide for Remission of Type 2 Diabetes: Multicentre, Double Blind, Randomised, Placebo Controlled Trial","Inclusion Criteria:\n\n1.T2D was diagnosed according to WHO standards in 1999. 2.18 years to 70years when signing the informed consent form. 3.Diet and exercise intervention alone before screening, or stable metformin (≥500 mg\u002F day and ≤2000mg\u002F day for at least 4 weeks), or a stable dose of SGLT2 inhibitor (minimum maintenance dose: Empagliflozin 10 mg\u002F day, dapagliflozin 5 mg\u002F day, canagliflozin 100 mg\u002F day, constant agliflozin 5 mg\u002F day, and etoagliflozin 5 mg\u002F day for at least 4 weeks) were still not well controlled after monotherapy, and the local laboratory test at screening was 6.5%≤HbA1c≤9.0%.\n\n4.Duration of type 2 diabetes ≤5 years at screening. 5.BMI≥24 kg\u002Fm2 at screening. 6.A stable diet and exercise lifestyle could be maintained during the study period.\n\n7.Subjects voluntarily sign informed consent and agree to strictly follow the requirements of this protocol.\n\nExclusion Criteria:\n\n1\\. Subjects who are considered by the investigator to be potentially allergic to the components of the study drug or to the drug in the same class.\n\n2.Weight change \\> 5% in 12 weeks before screening (chief complaint). 3. Use of any of the following drugs or treatments before screening:\n\n1. Use of a GLP-1R agonist or GLP-1R\u002FGCGR (glucagon receptor) agonist or GIPR (glucose-dependent insulinotropic polypeptide) within 2 months before screening receptor) \u002FGLP-1R agonist or GIPR\u002FGLP-1R\u002FGCGR agonist; Participants who discontinued a drug more than 2 months before screening because of lack of efficacy or intolerance were also excluded.\n2. Oral antidiabetic drugs other than background medications within 2 months before screening.\n3. Use of insulin for diabetes control within 3 months before screening, except for short-term use of insulin in acute conditions (cumulative ≤14 days), such as acute illness, hospitalization, or elective surgery. The interval between the last insulin treatment and screening day was less than 14 days.\n4. Weight-loss medications used within 1 month before screening or planned to be used during the trial, such as semaglutide, benaglutide, liraglutide, orlistat, sibutramine hydrochloride, phenylpropanolamine, chlorbendazole, phenylbutamine, lorcaserin hydrochloride, phentermine, phentermine\u002Ftopiramate, bupropion, and naltrexone\u002Fbupropion.\n5. Use of Chinese herbal medicine, other traditional medicines and health products with hypoglycemic effect within 2 months before screening.\n6. were receiving chronic (\\> 2 weeks) systemic glucocorticoids or had received glucocorticoids within 4 weeks before screening (topical, intraocular, intranasal, or inhaled administration were excluded).\n7. current use of central nervous system stimulants, excluding caffeinated beverages, at the time of screening.\n8. have participated in another clinical trial and received a trial drug within 3 months before screening.\n9. History of alcohol and drug abuse at screening. Mean weekly alcohol intake: more than 21 units for men and 14 units for women (1 unit = 360 ml of beer, or 150 ml of red wine, or 45 ml of distilled\u002Fliquor).\n\n4\\. There is a history or evidence of any of the following diseases:\n\n1. Previously diagnosed with type 1 diabetes (including latent autoimmune diabetes in adults, LADA), or positive for glutamic acid decarboxylase antibody (GADA) and other islet-related antibodies.\n2. Complications of diabetes occurred within 30 days before screening (ketosis acidosis, hyperosmolar diabetic state, or lactic acidosis).\n3. History of severe hypoglycemic episodes within 30 days before screening, defined as presenting with neurological hypoglycemic symptoms and requiring assistance from others to recover, or having no awareness of hypoglycemia or insufficient understanding of hypoglycemic symptoms in the past. Subjects who the researchers consider unable to communicate and understand hypoglycemic symptoms and appropriate treatment should also be excluded from this study.\n4. Previous history of acute or chronic pancreatitis, or blood amylase or lipase \\> 2.0×upper limit of normal value (ULN) during the screening period, or fasting triglycerides ≥ 5.64 mmol\u002FL (500 mg\u002Fdl).\n5. Previous history of gastroparesis or bariatric surgery, or clinically significant gastric emptying abnormalities as determined by the researcher.\n6. Previous proliferative diabetic retinopathy, or diabetic macular edema, or rapid progression of non-proliferative diabetic retinopathy or requiring urgent treatment.\n7. Acute or chronic hepatitis (except chronic hepatitis B), symptoms and signs of other liver diseases, or ALT \\> 3.0×ULN (ALT \\> 5.0×ULN for non-alcoholic fatty liver disease), or AST \\> 3.0×ULN, or total bilirubin (TBIL) \\> 2.0×ULN.\n8. Previous personal or family history of medullary thyroid carcinoma, patients with multiple endocrine neoplasia type 2, or serum calcitonin ≥ 50 ng\u002FL (pg\u002FmL), or thyroid function-related indicators TSH \\> 6 mIU\u002FL or \\\u003C 0.4 mIU\u002FL.\n9. Hyperthyroidism or hypothyroidism confirmed by clinical assessment and\u002For abnormal thyroid stimulating hormone (TSH) as determined by clinical evaluation, except for subjects on stable thyroid hormone replacement therapy for at least 2 months with normal thyroid function and expected unchanged dosage throughout the study period.\n10. Previously diagnosed with autonomic neuropathy, manifested as urinary retention, resting tachycardia, orthostatic hypotension, or diabetic diarrhea.\n11. Had a severe cardiovascular or cerebrovascular event within 3 months before screening.\n12. 12-lead ECG at screening shows a heart rate \\\u003C 50 beats\u002Fmin or \\> 100 beats\u002Fmin, ECG indicates active heart disease, or the researcher considers the ECG abnormality at screening would interfere with the interpretation of ECG results during the subsequent follow-up, especially excluding QTcF \\> 500 ms.\n13. Poorly controlled hypertension, systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg; or had adjusted antihypertensive drugs (dose or type) within 30 days before screening; evidence of renal artery stenosis, or unstable blood pressure (including orthostatic hypotension, etc.).\n14. Had active or untreated malignant tumors within 5 years before screening, or in a clinical remission period (skin basal cell carcinoma and squamous cell carcinoma, cervical carcinoma in situ, prostate carcinoma in situ, or papillary thyroid carcinoma with no recurrence after surgery, except for subjects without recurrence) during the screening period. 15) During the screening process, if the estimated glomerular filtration rate (eGFR) is less than 45 mL\u002Fmin\u002F1.73 m2, it is calculated using the CKD-EPI formula (see Appendix 2).\n\n16\\) A history of atopic reactions (clinical manifestations of severe or multiple allergies), or a clinically significant history of multiple or severe drug allergies, or intolerance to topical glucocorticoids, or severe post-treatment hypersensitivity reactions (including but not limited to erythema multiforme, linear immunoglobulin A dermatitis, toxic epidermal necrolysis, allergic reactions, angioedema or exfoliative dermatitis).\n\n17\\) Evidence of previous or during the screening period human immunodeficiency virus (HIV) infection or positive HIV antibody, or hepatitis B (HBV) antibody, or hepatitis C (HCV) antibody, or positive syphilis antibody.\n\n18\\) History of organ transplantation (except corneal transplantation), or preparing for organ transplantation.\n\n19\\) During the screening process, the investigator considers that there is a serious active and uncontrolled physical condition or history that may place the participant at risk during the use of the study drug or interfere with the interpretation of the efficacy and safety data of this study.\n\n20\\) A history of mental illness during the past or during the screening period, and the investigator considers that the participant is not suitable to participate in this study.\n\n21\\) Within the previous 3 months, the blood donation volume and\u002For blood loss volume was ≥ 450 mL or there was bone marrow donation, blood transfusion or severe blood loss, or there was hemoglobinopathy, hemolytic anemia, sickle cell anemia, or the blood hemoglobin was \\\u003C 110g\u002FL (for males) or \\\u003C 100g\u002FL (for females) during the screening, or there were any other known factors that may interfere with the HbA1c test results; 5. Pregnant or lactating women, or men or women with reproductive capacity who are unwilling to use contraception throughout the study period until 8 weeks after the end of the study.\n\n6\\. The investigator considers that the subject has any other factors that may affect the efficacy or safety evaluation of this study and is not suitable to participate in this study.","70 Years",{"count":249,"type":23},249,[121],"The purpose of this study is to investigate and efficacy of Mastitide for diabetes remission in Chinese type 2 diabetic subjects with poor glycemic control on diet or exercise therapy alone or metformin\u002Fsodium-glucose cotransporter (SGLT2) inhibitor monotherapy.",[29],"2026-08-11",{"date":154,"type":51},{"date":256,"type":23},"2026-09-30",{"date":258,"type":23},"2029-06-30",{"name":260,"class":162},"Yanbing Li",{"id":262,"slug":263,"hasResults":12,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":270,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":282},"100601580","phase-4-a-research-study-to-see-how-well-weekly-insulin-icodec-maintains-blood-sugar-levels-compared-to-daily-basal-insulins-in-adults-with-type-2-diabetes-100601580","NCT07112339","A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","EFFectiveness of Once-weekly Insulin ICodec Versus Once-daily Basal Insulin Analogues in an Insulin-naïve Type 2 diabEtes Population in Real-world cliNical pracTice- The EFFICIENT Pragmatic Study Effectiveness of Insulin Icodec in Real-world Clinical Practice","Inclusion Criteria:\n\n* Diagnosed with T2D greater than or equal to (≥) 180 days prior to the day of screening.\n* Treatment with any of the following non-insulin glucose-lowering medication(s) or combination regimen(s) at the time of screening:\n\nMetformin, Sulfonylureas, Meglitinides (glinides), dipeptidyl peptidase-4 (DPP-4) inhibitors, sodium-glucose cotransporter-2 (SGLT2) inhibitors, Thiazolidinediones, Alpha-glucosidase inhibitors, Oral combination products (for the allowed individual oral antidiabetic drugs), Oral or injectable glucagon-like peptide-1 (GLP-1) receptor agonists and Injectable dual glucose-dependent insulinotropic polypeptides (GIP) and GLP-1 receptor agonist.\n\n* Need of intensification with basal insulin, as indicated at the discretion of the investigator.\n* Recorded HbA1c value ≥7% within the last 90 days prior to randomization.\n\nExclusion Criteria:\n\n* Known or suspected hypersensitivity to study intervention(s) or related products.\n* Previous participation in this study. Participation is defined as signed informed consent.\n* Female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive method.\n* Participation (i.e., received any study intervention) in any interventional clinical study within 90 days before screening.\n* Any disorder which in the investigator's opinion might jeopardize participant's safety.",{"count":269,"type":23},586,[271],"PHASE4","This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.",[29],"2026-08-10",{"date":253,"type":51},{"date":277,"type":51},"2025-08-15",{"date":279,"type":23},"2028-03-23",{"name":281,"class":58},"Novo Nordisk A\u002FS",75,{"id":284,"slug":285,"hasResults":12,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":290,"targetDuration":4,"studyType":24,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},"100643855","a-research-study-comparing-how-well-different-doses-of-the-medicine-ubt251-lower-blood-sugar-in-people-with-type-2-diabetes-100643855","NCT07668388","A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion Criteria:\n\n* Male or female (sex assigned at birth, inclusive of all gender identities).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.\n* Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:\n\nmetformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.\n\n* HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol\u002Fmol)) (both inclusive) as assessed by central laboratory at screening.\n* Body mass index between 25.0 kg\u002Fm\\^2 and 50.0 kg\u002Fm\\^2 (both inclusive) at screening.\n\nExclusion Criteria:\n\n* Treatment with any medication (prescription or over-the counter) or alternative remedies for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire, question 8.",{"count":291,"type":23},300,[71],"The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.",[29],"2026-08-07",{"date":274,"type":51},{"date":298,"type":51},"2026-06-22",{"date":300,"type":23},"2027-11-15",{"name":281,"class":58},70,{"id":304,"slug":305,"hasResults":12,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":310,"targetDuration":4,"studyType":24,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":321},"100624924","a-research-study-comparing-how-well-different-doses-of-the-medicine-nnc0662-0419-lower-blood-sugar-in-people-with-type-2-diabetes-100624924","NCT07415954","A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes","Efficacy and Safety of Once-weekly Subcutaneous NNC0662-0419 in Participants With Type 2 Diabetes - a Dose-finding Study","Inclusion criteria\n\n* Male or female (sex at birth).\n* Age 18-75 years (both inclusive) at the time of signing the informed consent.\n* Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \\[mmol\u002Fmol\\]) (both inclusive) as assessed by central laboratory at screening.\n* Willingness to obtain a high weight loss (greater than \\[\\>\\] 25% of weight at baseline).\n\nExclusion criteria\n\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed.\n* Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.\n* Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.",{"count":311,"type":23},270,[71],"This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Semaglutide is an approved medication to treat type 2 diabetes.",[29],{"date":274,"type":51},{"date":317,"type":51},"2026-04-17",{"date":319,"type":23},"2027-10-01",{"name":281,"class":58},63,{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":24,"phases":331,"briefSummary":332,"conditions":333,"keywords":335,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":337,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":215},"100541400","food-insecurity-reduction--strategy-team-100541400","NCT06329375","Food Insecurity Reduction & Strategy Team","FIRST","Inclusion Criteria:\n\n* Diagnosis of Type 1 or Type 2 Diabetes Mellitus\n* Admitted to Stanford Healthcare inpatient unit\n* Residence in California at time of enrollment\n* Positive Screening for Food Insecurity\n* On a Healthcare Plan covered by Mom's Meals.\n\nExclusion Criteria:\n\n* Plans to be discharged to a skilled nursing facility.\n* Patients who prefer a language for which a short-form consent is not available.\n* No Home Address\n* Pregnant Participants.\n* No access to refrigerator.",{"count":330,"type":23},160,[121],"This study seeks to address the multifaceted challenges posed by food disparities and their negative consequences on health outcomes, via a comprehensive community health intervention program. Study objectives include:\n\n1. To describe the social-demographic and clinical factors associated with food insecurity in the hospitalized diabetic population.\n2. To design, implement and evaluate a nutrition program targeting the hospitalized diabetic population. The investigators will prospectively randomize the target population into either a nutrition program (Intervention), or state-of-art standard of care (SOC) in a 4:1 ratio. Participants in the intervention group will be provided the following two resources in addition to SOC: 1) Enhanced access to nutritious food (twice daily meal delivery up to 90 days post-discharge) 2) Education at discharge and continuing outreach to enhance knowledge for better diet and food options.\n3. To enhance community engagement and develop a systematic implementation plan for long-term roll-out of the nutrition program.",[29,334,205],"Food Insecurity",[336],"inpatient",{"date":253,"type":51},{"date":339,"type":51},"2024-10-07",{"date":341,"type":23},"2027-01-15",{"name":343,"class":162},"Stanford University",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":352,"maxAge":353,"enrollmentInfo":354,"targetDuration":4,"studyType":24,"phases":355,"briefSummary":357,"conditions":358,"keywords":361,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":368,"lastUpdatePostDateStruct":369,"startDateStruct":370,"completionDateStruct":371,"leadSponsor":373,"locationsCount":4},"100651260","phase-1-pre-emptive-insulin-to-prevent-high-glucose-after-a-knee-steroid-injection-in-adults-with-type-2-diabetes-100651260","NCT07757464","Pre-emptive Insulin to Prevent High Glucose After a Knee Steroid Injection in Adults With Type 2 Diabetes","A Phase 2 Randomized Trial of Pre-emptive NPH Insulin Versus Usual Reactive Diabetes Management for Preventing Hyperglycaemia After Intra-articular Triamcinolone Acetonide Injection in Adults With Type 2 Diabetes and Knee Osteoarthritis","PREVENT-SIH","Inclusion Criteria:\n\n* Age 40 to 80 years at consent.\n* Documented diagnosis of type 2 diabetes for at least 6 months.\n* HbA1c from 6.5% through 9.0% measured within 30 days before randomisation.\n* Symptomatic osteoarthritis of one knee for which the treating clinician has independently determined that an intra-articular corticosteroid injection is clinically indicated.\n* Planned administration of one intra-articular injection of triamcinolone acetonide crystalline suspension 40 mg into the index knee.\n* Diabetes managed without insulin, sulfonylureas or meglitinides.\n* Permitted glucose-lowering medications at stable doses for at least 30 days before randomisation.\n* Estimated glomerular filtration rate at least 45 mL\u002Fmin\u002F1.73 m² within 60 days before randomisation.\n* Capillary glucose from 90 through 250 mg\u002FdL immediately before the injection.\n* Ability and willingness to perform scheduled capillary glucose testing, administer or receive subcutaneous insulin if assigned, follow hypoglycaemia instructions and remain contactable through day 7.\n* Ability to wear the study continuous glucose monitoring device and provide informed consent.\n\nExclusion Criteria:\n\n* Type 1 diabetes, latent autoimmune diabetes in adults, pancreatogenic diabetes or another specific diabetes type requiring insulin.\n* Current basal, prandial, premixed or pump insulin treatment.\n* Current sulfonylurea or meglitinide treatment.\n* HbA1c below 6.5% or above 9.0%.\n* Capillary glucose below 90 mg\u002FdL or above 250 mg\u002FdL immediately before injection.\n* Fasting glucose above 250 mg\u002FdL, random glucose above 300 mg\u002FdL, clinically significant ketonaemia or hyperglycaemia requiring immediate treatment during screening.\n* Estimated glomerular filtration rate below 45 mL\u002Fmin\u002F1.73 m².\n* Severe hepatic impairment or another condition expected to materially alter insulin clearance or hypoglycaemia risk.\n* Level 3 hypoglycaemia requiring third-party assistance during the previous 6 months.\n* Documented impaired awareness of hypoglycaemia.\n* Pregnancy, planned pregnancy during study participation or breastfeeding.\n* Oral, intravenous or intramuscular corticosteroid use within 30 days before the study injection.\n* Any intra-articular, epidural, periarticular or soft-tissue corticosteroid injection within 30 days before the study injection.\n* Planned additional systemic or injected corticosteroid exposure before the day-7 assessment.\n* Acute febrile illness, active systemic infection or acute deterioration in health at screening or injection.\n* Suspected septic arthritis, infection over the injection site, prosthetic index knee, uncontrolled bleeding disorder or another contraindication to knee injection.\n* Known allergy or clinically significant hypersensitivity to triamcinolone acetonide, human NPH insulin, insulin aspart, protamine, lidocaine or required excipients.\n* Known allergy to continuous glucose monitoring adhesive or a skin condition preventing sensor use.\n* Cognitive, visual, physical or social limitation that would prevent safe glucose testing, insulin administration, hypoglycaemia treatment or study contact.\n* Participation in another interventional study likely to affect glucose or corticosteroid response.\n* Any condition that, in the investigator's documented judgement, makes participation unsafe for a reason not otherwise captured above.","40 Years","80 Years",{"count":134,"type":23},[356,71],"PHASE1","Steroid injections used to treat painful joints can temporarily increase glucose levels in people with type 2 diabetes. This study will test whether a short course of pre-emptive neutral protamine Hagedorn, NPH, insulin can reduce high glucose after a standard corticosteroid injection into the knee.\n\nAdults with type 2 diabetes who are scheduled to receive one intra-articular injection of triamcinolone acetonide 40 mg for knee osteoarthritis will be randomly assigned to one of two groups. The experimental group will receive a prespecified NPH insulin regimen beginning immediately after the injection and continuing for three doses. The comparison group will continue usual reactive diabetes management without pre-emptive NPH insulin.\n\nBoth groups will use blinded continuous glucose monitoring and scheduled capillary glucose testing. The main outcome is the percentage of continuous glucose monitoring time above 180 mg\u002FdL during the first 72 hours after the corticosteroid injection. Hypoglycaemia, rescue treatment, healthcare contacts, treatment burden, acceptability and adverse events will also be assessed.",[29,359,360],"Hyperglycemia Due to Type 2 Diabetes Mellitus","Osteoarthritis, Knee",[362,363,364,365,366,185,367],"Steroid-induced hyperglycaemia","Glucocorticoid-induced hyperglycaemia","Intra-articular corticosteroid injection","Triamcinolone acetonide","NPH insulin","Knee osteoarthritis","2026-08-05",{"date":253,"type":51},{"date":274,"type":23},{"date":372,"type":23},"2027-01-30",{"name":374,"class":162},"Shifa International Hospital",{"id":376,"slug":377,"hasResults":12,"nctId":378,"briefTitle":379,"officialTitle":379,"acronym":380,"eligibilityCriteria":381,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":382,"targetDuration":4,"studyType":24,"phases":384,"briefSummary":385,"conditions":386,"keywords":387,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":392,"completionDateStruct":393,"leadSponsor":395,"locationsCount":215},"100554043","evaluation-of-the-effectiveness-of-extending-the-passerelle-system-for-prescribing-adapted-physical-activity-to-patients-with-type-2-diabetes-in-nouvelle-aquitaine-france-100554043","NCT06493955","Evaluation of the Effectiveness of Extending the \"Passerelle\" System for Prescribing Adapted Physical Activity to Patients With Type 2 Diabetes in Nouvelle-AQUItaine (France)","PAPA-NAQUI","Inclusion Criteria:\n\n* Patients with type 2 diabetes with initial diagnosis of fasting blood glucose \\> 1.26 g\u002Fl on 2 occasions\n* Patient aged 18 or over\n* Patient with a Marshall score ≤ 3\n* Patient residing in the Nouvelle-Aquitaine region\n* Patient eligible for the \"Passerelle\" program\n* Patient willing to participate\n* Patient agreeing to take part in the study and having signed an informed consent form\n* Person affiliated or benefiting from a social security scheme.\n\nExclusion Criteria:\n\n* Patient with any other unstabilized pathology:\n* Cardiovascular: unstable angina, stress angina, malignant hypertension, recent myocardial infarction, unstabilized heart disease\n* Pulmonary: uncontrolled asthma, COPD exacerbation\n* Endocrine: diabetes with HbA1c \\> 9%, plantar perforator disease\n* Pregnant patient\n* Diabetic patient with contraindication to APA prescription\n* Patient under court protection",{"count":383,"type":23},308,[121],"Type 2 diabetes is on the increase worldwide. Two major risk factors have been identified: overweight and physical inactivity. National and international recommendations encourage general practitioner to guide patients in changing their lifestyle. As regards physical activity in France, general practitioner have been able to prescribe adapted physical activity (APA) for their patients since 2016. In type 2 diabetes, it is known that physical activity interventions are cost-effective. However, these interventions are often too expensive and far removed from real life. It is also known that the benefits of intervention increase up to 18 months, then diminish to zero at 36 months. In Nouvelle-Aquitaine, France, the \"PEPS Sport-santé network\", offers physical activity coaching for patients who are not sufficiently active: the \"Passerelle\" program. Patients can benefit from a weekly physical activity session for 6 months.\n\nThe investigators would therefore like to assess whether extending the existing \"Passerelle program\" by 6 months, with one session every 15 days, is effective in maintaining the volume of physical activity 12 months after the end of the intervention.",[29],[29,388,389],"Adapted Physical Activity","general practice","2026-08-04",{"date":295,"type":51},{"date":157,"type":23},{"date":394,"type":23},"2029-09",{"name":396,"class":162},"University Hospital, Bordeaux",{"id":398,"slug":399,"hasResults":12,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":405,"maxAge":406,"enrollmentInfo":407,"targetDuration":4,"studyType":24,"phases":409,"briefSummary":410,"conditions":411,"keywords":413,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":415,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":215},"100384380","surgical-treatment-for-obesity-related-disease-and-onco-metabolic-surgery-100384380","NCT04284943","Surgical TreAtment for Obesity Related Disease and Onco-Metabolic Surgery","A Randomized Controlled Trial Comparing Billroth II Reconstruction Versus Conventional Roux-en-Y Reconstruction Versus Long Limb Roux-en-Y Reconstruction for Glycemic Control in Patients With Concurrent Type 2 Diabetes and Gastric Cancer","STARDOM","Inclusion Criteria:\n\n* Distal gastric adenocarcinoma diagnosed pathologically under preoperative endoscopic biopsy, and clinical stage I-II\n* Body mass index ≥ 23 kg\u002Fm2\n* Type 2 diabetes and HbA1c ≥ 6.5%\n\nExclusion Criteria:\n\n* Insulin usage for glycemic control at the time of screening evaluation\n* Prior gastrointestinal surgery including splenectomy, hepatobiliary and pancreatic surgery (except hemorrhoidectomy, herniorrhaphy, and appendectomy)\n* Abdominal, thoracic, pelvic and\u002For obstetric-gynecologic surgery within 3 months\n* Cardiovascular conditions including significant known CAD, uncompensated congestive heart failure, history of stroke, or uncontrolled hypertension. Subjects with CAD that have been successfully treated with CABG or PCI, and have no evidence of active ischemia are eligible\n* Kidney disease including renovascular hypertension, renal artery stenosis, or end-stage renal disease\n* Chronic liver disease including liver cirrhosis, alpha-1 antitrypsin deficiency\n* Gastrointestinal disorders including inflammatory bowel disease (Crohn's disease or ulcerative colitis) or any malabsorptive disorders\n* Psychiatric disorders including dementia, active psychosis, history of suicide attempts, alcohol or drug abuse within 12 months\n* Severe pulmonary disease defined as FEV1 \\\u003C50% of predicted value\n* Anemia defined as hemoglobin less than 8 in females and 10 in males\n* Malignancy within 5 years (except squamous cell and basal cell cancer of the skin). Subjects diagnosed with early or stage I cancer than have been successfully treated are eligible per investigator discretion\n* Frail elderly (Rockwood Clinical Frailty Scale ≥5)\n* Any condition or major illness that, in the investigator's judgement, places the subject at undue risk by participating in the study\n* Unable to understand the risks, realistic benefits and compliance requirements of each program\n* Use of investigational therapy or participation in any other clinical trial within 3 months\n* Geographic inaccessibility\n* Pregnancy","20 Years","69 Years",{"count":408,"type":23},120,[121],"This is a prospective, multi-center, randomized controlled trial to compare Billroth II reconstruction versus conventional Roux-en-Y reconstruction versus long limb Roux-en-Y reconstruction for glycemic control in patients with concurrent type 2 diabetes and gastric cancer.",[412,29],"Gastric Cancer",[412,29,414],"Subtotal Gastrectomy",{"date":295,"type":51},{"date":417,"type":51},"2020-12-01",{"date":419,"type":23},"2027-12",{"name":421,"class":162},"Korea University Anam Hospital",{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":427,"acronym":428,"eligibilityCriteria":429,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":247,"enrollmentInfo":430,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":432,"conditions":433,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":215},"100560002","harnessing-macrophage-lysosomal-lipid-metabolism-in-obesity-atm-100560002","NCT06571474","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity (ATM)","Harnessing Macrophage Lysosomal Lipid Metabolism in Obesity-Associated Diseases","ATM","Inclusion Criteria :\n\n* age: ≥18 but ≤70 years\n* not pregnant or breastfeeding\n* weight stable and sedentary before enrollment\n* no use tobacco products, excessive amounts of alcohol, or dietary supplements, or medications known to or suspected to affect glucose and lipid metabolism (aside from certain medications used to treat diabetes in the metabolically abnormal obesity \\[MAO\\]-Type 2 Diabetes group)\n* no evidence of significant organ system dysfunction or disease (e.g. chronic severe kidney disease, cancer)\n* participants must fulfil all of the following group-specific inclusion criteria below:\n\nLean group:\n\n* Body mass index (BMI) ≥18.5 but \\\u003C25.0 kg\u002Fm2\n* Intrahepatic triglyceride (IHTG) content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* Hemoglobin A1C (HbA1c) \\\u003C5.7 %\n\nMetabolically normal obesity (MNO) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\\u003C5%\n* fasting blood glucose concentration: \\\u003C100 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: \\\u003C140 mg\u002Fdl\n* HbA1c \\\u003C5.7 %\n\nMetabolically abnormal obesity (MAO)-insulin resistance and non-alcoholic fatty liver disease (NAFLD) group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* IHTG content \\>7.5%\n* fasting blood glucose concentration: ≥100 but \\\u003C126 mg\u002Fdl\n* blood glucose concentration 2 h after a 75 g oral glucose challenge: ≥140 but \\\u003C200 mg\u002Fdl\n* HbA1c: ≥5.7 but \\\u003C6.4 %\n\nMAO-type 2 diabetes group:\n\n* BMI ≥30.0 but \\\u003C45.0 kg\u002Fm2\n* clinical diagnosis of type 2 diabetes or fasting blood glucose concentration \\>126 mg\u002Fdl or blood glucose concentration 2 h after a 75 g oral glucose challenge\\>200 mg\u002Fdl or HbA1c \\>6.4 % without medication if not diagnosed and medically treated for diabetes\n\nExclusion Criteria:\n\n\\- Individuals that do not meet all inclusion Criterion",{"count":431,"type":23},60,"The goal of this study is to evaluate the role of transcription factor EB (TFEB) in adipose (fat) tissue macrophages (ATM) in regulating adipose tissue and systemic metabolic function in obesity. The investigators will assess the differences in ATM lipid metabolism in people with metabolically abnormal obesity and lean individuals.\n\nBoth groups will have:\n\n* screening visit\n* imaging (body composition testing - dual-energy x-ray absorptiometry (DEXA) scans, magnetic resonance imaging \\[MRI\\] and magnetic resonance spectroscopy \\[MRS\\] scans)\n* Overnight visit with intravenous infusion (IV), muscle, and fat tissue biopsies",[74,434,29,435],"Non-Alcoholic Fatty Liver Disease","Healthy","2026-08-03",{"date":438,"type":51},"2026-08-06",{"date":440,"type":51},"2024-08-01",{"date":442,"type":23},"2028-03",{"name":444,"class":162},"Bettina Mittendorfer",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":451,"eligibilityCriteria":452,"healthyVolunteers":12,"sex":18,"minAge":67,"maxAge":4,"enrollmentInfo":453,"targetDuration":4,"studyType":24,"phases":455,"briefSummary":456,"conditions":457,"keywords":459,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":469},"100538872","safer-aging-with-diabetes-monitoring-100538872","NCT06296485","Safer Aging With Diabetes Monitoring","Pragmatic Clinical Trial of Continuous Glucose Monitoring-based Interventions for Safe Insulin Use in High-Risk Older Adults With Type 2 Diabetes","SAGE","Inclusion Criteria:\n\n* Age 75 years and older\n* Diagnosis of Type 2 Diabetes\n* Current treatment with insulin\n* Increased hypoglycemia risk (prior year hypoglycemia by self-report or utilization)\n* Able to communicate in English\n* Able to access email and the Internet\n\nExclusion Criteria:\n\n* On renal dialysis\n* Dementia\n* Pacemaker or Automatic Implantable Cardioverter Defibrillator\n* Using insulin pump\n* Severe Mental Illness\n* Severe Visual Impairment\n* In Hospice\n* Current or recent CGM use",{"count":454,"type":23},360,[121],"Older adults with type 2 diabetes are at higher risk for severe hypoglycemia and its related complications (including hospitalization and death) when taking insulin. This study proposes to evaluate, in a randomized clinical trial, a strategy of safe insulin prescribing based on an educational program that leverages continuous glucose monitoring to support older adults at high risk for hypoglycemia. If the aims of this project are achieved, this novel care strategy could be widely applied to reduce severe hypoglycemia episodes in older, high-risk adults with type 2 diabetes.",[29,458],"Hypoglycemia",[458,460,461],"Diabetes Education","Continuous Glucose Monitor",{"date":390,"type":51},{"date":464,"type":51},"2024-05-01",{"date":466,"type":23},"2028-01-31",{"name":468,"class":162},"Kaiser Permanente",6,{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":4,"eligibilityCriteria":476,"healthyVolunteers":116,"sex":18,"minAge":19,"maxAge":67,"enrollmentInfo":477,"targetDuration":4,"studyType":24,"phases":479,"briefSummary":480,"conditions":481,"keywords":482,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":487,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":240},"100640678","phase-1-a-trial-evaluating-amg-127-in-healthy-participants-and-participants-with-type-2-diabetes-mellitus-100640678","NCT07590193","A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus","A Phase 1 Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus","Inclusion Criteria for Part A and B\n\n* Participant must be 18-65 years of age\n* Participant must be overtly healthy\n\nInclusion Criteria for Part C\n\n* Participant must be 40-75 years of age\n* Confirmed diagnoses of T2DM\n\nExclusion Criteria for Part A and B\n\n* History of hypotension, syncope, or orthostatic intolerance\n* Systolic blood pressure \\>140 millimeters of mercury (mmHg) or diastolic blood pressure \\>90 mmHg\n\nExclusion Criteria for Part C\n\n* Hemoglobin A1c (HbA1c) \\>10% within the last 3 months\n* History of hypotension, syncope, or orthostatic intolerance\n* Systolic blood pressure \\>160 mmHg or diastolic blood pressure \\>100 mmHg",{"count":478,"type":23},162,[356],"The main objective of this trial is to assess the safety and tolerability of AMG 127 as single dose and multiple doses in healthy participants and participants with type 2 diabetes mellitus (T2DM).",[29],[483,484,485],"AMG 127","healthy participants","type 2 diabetes mellitus","2026-07-31",{"date":436,"type":51},{"date":489,"type":51},"2026-06-11",{"date":491,"type":23},"2027-10-02",{"name":493,"class":58},"Amgen",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":4,"eligibilityCriteria":500,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":501,"targetDuration":4,"studyType":24,"phases":503,"briefSummary":504,"conditions":505,"keywords":507,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":486,"lastUpdatePostDateStruct":510,"startDateStruct":511,"completionDateStruct":513,"leadSponsor":515,"locationsCount":215},"100519690","continuous-glucose-metrics-in-patients-with-gastroparesis-in-type-1-or-type-2-diabetes-100519690","NCT06046833","Continuous Glucose Metrics in Patients With Gastroparesis in Type 1 or Type 2 Diabetes","Glucose Metrics Using Freestyle Libre 3 Real-Time Continuous Glucose Monitor (rtCGM) in Patients With Gastroparesis in Type 1 or Type 2 Diabetes: Investigator Initiated Pilot Study","Inclusion Criteria:\n\n* Over the age of 18 years.\n* Hemoglobin A1c ≤11% within the last 6 months.\n* Patients with diagnosis of type 1 Diabetes or type 2 Diabetes for at least one year.\n* Normal thyroid-stimulating hormone (TSH) within the last year.\n* No episodes of diabetic ketoacidosis (DKA), Hyperosmolar Hyperglycemic Status (HHS), or hypoglycemia in the past 2 weeks requiring ER visit or hospitalization.\n* Symptoms of gastroparesis have been present for at least the past 3 months, in patients with gastroparesis.\n* In patients with gastroparesis, documented delayed gastric emptying on scintigraphy and\u002For wireless motility capsule (Smart Pill) as defined by greater than 10% retention at 4 hours or greater than 4-hour gastric transit time (GTT) in the past five years.\n* Patients using a Smartphone (iPhone or Android) compatible with LibreView App.\n\nExclusion Criteria:\n\n* Hemoglobin A1c of \\>11% at enrollment.\n* Advanced chronic kidney disease (serum creatinine of \\>2 mg\u002FdL or estimated glomerular filtration rate (eGFR) \\\u003C30mL\u002Fmin\u002F1.73m² using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula).\n* Advanced and significant cardiovascular disease or unstable angina.\n* Advanced liver disease that may affect glucose profiles.\n* Post-transplant patients.\n* History of gastric surgery.\n* Patients with symptoms secondary to celiac disease (e.g. diarrhea, nausea, vomiting, abdominal pain) at the time of the enrollment.\n* Pregnancy or women of reproductive age group not taking adequate precautions for pregnancy for 28 days.\n* Patients on steroids or immunomodulators or chemoradiation that might affect glucose profiles.\n* Patients on opiates or glucagon-like peptide-1 (GLP-1) agonists (Ozempic, Wegovy, Mounjaro, Trulicity). If previously taking these medications, patients can be enrolled after 2 weeks of the last dose.\n* Patient on recreational or illicit drugs (i.e., marijuana, opiates, cocaine, etc.).\n* Patients on motility medications such as Reglan (Metoclopramide), Motegrity (Prucalopride), Cisapride, Domperidone, Erythromycin. If previously taking any of these medications, patients can be enrolled after 1 week of the last dose.\n* Clinically significant abnormalities on upper GI endoscopy.\n* Presence of imaging evidence of gastric or intestinal obstruction.\n* Patient previously participated in the study.",{"count":502,"type":23},50,[121],"A pilot study to evaluate and compare glucose metrics using a real-time continuous glucose monitor (FreeStyle Libre 3 sensor) between patients with diabetes and gastroparesis and those with diabetes without gastroparesis.",[29,205,506],"Gastroparesis With Diabetes Mellitus",[508,509,461],"Gastroparesis","Diabetes",{"date":436,"type":51},{"date":512,"type":51},"2024-01-08",{"date":514,"type":23},"2026-12",{"name":516,"class":162},"Samita Garg",{"id":518,"slug":519,"hasResults":12,"nctId":520,"briefTitle":521,"officialTitle":521,"acronym":4,"eligibilityCriteria":522,"healthyVolunteers":12,"sex":18,"minAge":352,"maxAge":247,"enrollmentInfo":523,"targetDuration":4,"studyType":24,"phases":525,"briefSummary":526,"conditions":527,"keywords":528,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":533,"startDateStruct":534,"completionDateStruct":536,"leadSponsor":538,"locationsCount":4},"100642395","effectiveness-of-low-calorie-mind-hk-diet-and-very-low-calorie-diet-on-glycemic-control-and-cardiovascular-outcomes-in-adults-with-type-2-diabetes-a-12-week-randomized-controlled-trial-100642395","NCT07635121","Effectiveness of Low-Calorie MIND-HK Diet and Very Low-Calorie Diet on Glycemic Control and Cardiovascular Outcomes in Adults With Type 2 Diabetes: A 12-Week Randomized Controlled Trial","Inclusion Criteria:\n\n1. aged 40 to 70 years old;\n2. diagnosed with Type II DM; and\n3. Chinese ethnicity and able to speak and understand Cantonese.\n\nExclusion Criteria:\n\n1. patients on dialysis;\n2. Type I and Type II DM patients with insulin use;\n3. allergic to more than one type of food in the Low-calorie MIND-HK diet and very Low-calorie MIND- HK diet (e.g. nuts, berries, olive oil, or fish);\n4. Pregnant or Breastfeeding Women;\n5. Individuals with severe mental health conditions including severe depression, anxiety or other mental issues may struggle with the psychological demands of a very low calorie diet;\n6. People with low BMI less than 18.5;\n7. participation ni any dietary program within the past 3 months.",{"count":524,"type":23},180,[121],"The objective of this project is to assess the effectiveness of a low-calorie and very low-calorie Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND-HK) diet in improving glycemic control and cardiovascular outcomes in adults with T2DM. A total of 180 participants aged 40 to 70, diagnosed with T2DM, will be recruited and randomized into three groups: intervention 1 following the low-calorie MIND-HK diet, intervention 2 following the very low-calorie diet, and an attention control group. The two intervention groups will attend four in-person nutrition counseling sessions (one per week, 60 minutes per session, followed by a 30-minute Q\\&A) at a community centre and will use KetoMetrics Breath Ketone System and dietary mobile app, to track diet and monitor daily ketone levels for early signs of ketosis that may lead to diabetic ketoacidosis (DKA). The attention control group will receive an equal amount of attention through four in-person infectious disease counseling sessions. The primary outcome will be HbA1c levels. Secondary outcomes include fasting blood glucose, lipid profile, blood pressure, body mass index, waist circumference, breath ketone, scores from the Summary Diabetes Self-Care Activities (SDSCA) Questionnaire, and MIND diet scores. This study will contribute to the growing body of evidence on dietary interventions for managing T2DM in adults.",[148],[529,530,531],"Very low-calorie MIND-HK diet","Low-calorie MIND-HK diet","KetoMetrics Breath Ketone System","2026-07-30",{"date":486,"type":51},{"date":535,"type":23},"2026-07-01",{"date":537,"type":23},"2029-01-31",{"name":539,"class":162},"Hong Kong Metropolitan University",{"id":541,"slug":542,"hasResults":12,"nctId":543,"briefTitle":544,"officialTitle":544,"acronym":545,"eligibilityCriteria":546,"healthyVolunteers":12,"sex":547,"minAge":20,"maxAge":4,"enrollmentInfo":548,"targetDuration":4,"studyType":24,"phases":550,"briefSummary":551,"conditions":552,"keywords":553,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":532,"lastUpdatePostDateStruct":560,"startDateStruct":561,"completionDateStruct":563,"leadSponsor":565,"locationsCount":215},"100625908","phase-3-investigating-the-impact-of-glp-1-ra-therapy-on-osteosarcopenia-in-older-female-adults-with-diabetes-100625908","NCT07428746","Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes","GLOW","Inclusion Criteria:\n\n* Postmenopausal women aged 65 years or older\n* Has type 2 diabetes\n* Body Mass Index (BMI) ≥27 kg\u002Fm² to max 40kg\u002Fm2 (inclusive)\n* Hemoglobin A1c \\>7% within 3 months of the first visit.\n* Willingness and ability to comply with all study procedures, including fasting requirements for certain visits.\n* No osteoporosis confirmed on DEXA scan within 12 months\n* Able to provide informed consent and participate in all study assessments\n\nExclusion Criteria:\n\n* Patients with type 1 diabetes mellitus or other types of diabetes that are not T2D\n* eGFR \\\u003C30 ml\u002Fmin in the last 3 months\n* Patients with a history of treatment with anti-osteoporosis agents\n* Documented primary or secondary osteoporosis on a DEXA scan within the last 12 months, or are on osteoporosis therapies\n* Documented presence of prosthesis or devices in the spine or hip\n* Previous fragility fracture\n* Males\n* Moderate to severe gastroesophageal reflux disease based on patient history.\n* Inability to comply with the treatment protocol or to understand the consent form.\n* Aspartate aminotransferase (AST) \\> 3 times normal or alanine aminotransferase (ALT) \\> 3 times the normal\n* Subjects with uncontrolled thyroid or parathyroid disease that may influence the study results.\n* Personal or family history of medullary thyroid carcinoma.\n* Personal or family history of multiple endocrine neoplasia type 2 syndrome.\n* Personal history of gastroparesis, celiac disease, hypogonadism, severe COPD, hypopituitarism, or Cushing's disease\n* Personal history of severe diabetic retinopathy.\n* Known serious hypersensitivity, including anaphylaxis and angioedema, to semaglutide or any of its excipients.\n* Any of the following drugs or treatments were used within 6 months before screening: treated with GLP-1RA, GIP analogues, pioglitazones\n* Concomitant treatment with GLP-1 receptor agonist therapy\n* Long-term intravenous, oral, and intra-articular administration of high-dose corticosteroids within 2 months before screening (more than 7 days in a row)\n* Use of weight control drugs or surgery that can lead to weight changes during the last 6 months before screening, or are currently in the weight loss plan and are not in the maintenance stage\n* Incarcerated individuals","FEMALE",{"count":549,"type":23},20,[26],"The goal of this study is to learn how GLP-1 receptor agonist therapy affects muscle and bone health in older females over age 65 with type 2 diabetes.\n\nThe main question it aims to answer is whether or not 6 months of GLP-1 RA therapy affects muscle strength.\n\nParticipants will:\n\n* Receive GLP-1 RA therapy as part of their routine clinical care\n* Complete muscle strength assessments (hand grip strength, Timed Up and Go test)\n* Provide blood samples for bone turnover markers\n* Undergo bone mineral density testing",[29],[554,555,556,557,558,559],"GLP-1 Receptor analogs","Semaglutide","DEXA","Osteosarcopenia","Bone Mineral Density","Bone turnover markers",{"date":436,"type":51},{"date":562,"type":51},"2026-05-07",{"date":564,"type":23},"2028-11",{"name":214,"class":162},{"id":567,"slug":568,"hasResults":12,"nctId":569,"briefTitle":570,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":116,"sex":18,"minAge":573,"maxAge":67,"enrollmentInfo":574,"targetDuration":576,"studyType":144,"phases":4,"briefSummary":577,"conditions":578,"keywords":581,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":589,"completionDateStruct":590,"leadSponsor":591,"locationsCount":215},"100649318","is-serum-irisin-level-a-biomarker-in-diabetic-polyneuropathy-100649318","NCT07734597","Is Serum Irisin Level a Biomarker in Diabetic Polyneuropathy?","Evaluation of Serum Irisin Levels as a Potential Biomarker in Patients With Diabetic Polyneuropathy: A Single-center Prospective Cross-sectional Observational Study","Inclusion Criteria:\n\n* Age between 30 and 75 years\n* Diagnosis of Type 2 Diabetes Mellitus for at least 1 year (for diabetic groups)\n* Ability to understand and sign informed consent\n* Willingness to participate in the study\n\nExclusion Criteria:\n\n* Neuropathy due to causes other than diabetes (e.g., vitamin B12 deficiency, chronic alcohol use, chemotherapy-induced neuropathy)\n* Chronic kidney disease (eGFR \\\u003C60 mL\u002Fmin\u002F1.73 m²)\n* Active infection\n* Myopathies or other muscle diseases\n* Central nervous system diseases (e.g., stroke, Parkinson disease)\n* Severe orthopedic conditions impairing mobility\n* Inability or unwillingness to provide informed consent","30 Years",{"count":575,"type":23},81,"12 Weeks","Diabetic polyneuropathy is a common complication of type 2 diabetes mellitus associated with sensory impairment and functional disability. Irisin is a myokine that has been implicated in glucose metabolism and neuroprotection. This prospective observational case-control study aims to evaluate serum irisin concentrations in patients with diabetic polyneuropathy compared with diabetic patients without neuropathy and healthy controls, and to investigate whether serum irisin may serve as a biomarker for diabetic polyneuropathy.",[579,580,148],"Polyneuropathies","Diabetic Complications Neurological",[582,583,584,585],"Biomarker","Type 2 Diabetes Mellitus","Diabetic polyneuropathies","Serum Irisin","2026-07-27",{"date":588,"type":51},"2026-07-29",{"date":532,"type":23},{"date":256,"type":23},{"name":592,"class":162},"GÜLDEN ANATACA",{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":599,"eligibilityCriteria":600,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":601,"targetDuration":4,"studyType":24,"phases":603,"briefSummary":604,"conditions":605,"keywords":607,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":618,"startDateStruct":620,"completionDateStruct":622,"leadSponsor":624,"locationsCount":215},"100643182","aim-met-ai-guided-microbiome-targeted-nutrition-for-glycemic-improvement-in-type-2-diabetes-100643182","NCT07622628","AIM-MET: AI-Guided Microbiome-Targeted Nutrition for Glycemic Improvement in Type 2 Diabetes","A 24-Week Randomized, Masked, Placebo-Controlled Trial of an AI-Guided Microbiome-Targeted Nutritional Intervention for Glycemic Improvement in Adults With Type 2 Diabetes: The AIM-MET Trial","AIM-MET","Inclusion Criteria:\n\nAdults aged 18 to 65 years.\n\nEstablished diagnosis of type 2 diabetes mellitus documented in the medical record, supported by American Diabetes Association diagnostic criteria on at least one prior occasion.\n\nHbA1c 6.8% to 8.2% at screening, measured by an NGSP-certified central laboratory assay; confirmed on a repeat sample if discordant with prior records or if the screening value is at the upper or lower boundary.\n\nBody mass index 18.5 to 40.0 kg\u002Fm2 at screening.\n\nStable background glucose-lowering therapy for at least 3 months before randomization, restricted to metformin, a DPP-4 inhibitor, and\u002For an SGLT2 inhibitor, either alone or in combination.\n\nDocumented body-weight stability, defined as no more than +\u002F-5% or +\u002F-3 kg, whichever is smaller, self-reported body-weight change during the 3 months before screening.\n\nWilling and able to provide written informed consent.\n\nWilling and able to comply with trial visits, study product use, fasting blood sampling, stool sampling, and the study assessment schedule.\n\nWilling to receive standardized lifestyle counselling during the 24-week blinded period and to maintain stable background diabetes management as clinically directed.\n\nNo systemic antibiotic use within 8 weeks before randomization.\n\nNo probiotic, prebiotic, synbiotic, or postbiotic supplement use within 8 weeks before randomization.\n\nStable hypertension, dyslipidaemia, and stable thyroid replacement therapy are permitted if medication has been initiated and the dose unchanged for at least 3 months before randomization.\n\nExclusion Criteria:\n\nType 1 diabetes, latent autoimmune diabetes of adults, pancreatogenic diabetes, maturity-onset diabetes of the young, gestational diabetes as the current diagnosis, or any non-type-2 form of diabetes.\n\nHbA1c less than 6.8% or greater than 8.2% at screening.\n\nCurrent use of GLP-1 receptor agonists or GLP-1\u002FGIP co-agonists, or use within 12 months before randomization.\n\nCurrent use of basal, prandial, or premixed insulin, or any insulin use within 6 months before randomization.\n\nCurrent use of sulfonylureas or meglitinides, or use within 3 months before randomization.\n\nCurrent use of anti-obesity pharmacotherapy or use within 6 months before randomization, including orlistat, naltrexone\u002Fbupropion, phentermine\u002Ftopiramate, or other agents with a primary anti-obesity indication.\n\nRecurrent severe hypoglycaemia or hypoglycaemia unawareness.\n\nPlanned initiation or dose escalation of glucose-lowering medication, anti-obesity medication, or systemic corticosteroids during the 24-week trial period in the judgment of the treating clinician.\n\nHistory of bariatric surgery at any time.\n\nGastrointestinal surgery other than appendectomy or uncomplicated cholecystectomy.\n\nActive inflammatory bowel disease, coeliac disease, microscopic colitis, chronic pancreatitis, malabsorption syndrome, or chronic severe gastrointestinal disease likely to affect absorption or trial adherence.\n\nAcute gastroenteritis within 4 weeks before randomization.\n\nColonoscopy bowel preparation within 12 weeks before randomization.\n\nFaecal microbiota transplantation within 12 months before randomization.\n\nActive or recent malignancy within 6 months, except adequately treated non-melanoma skin cancer.\n\nStage 3b to 5 chronic kidney disease, defined as estimated glomerular filtration rate less than 45 mL\u002Fmin\u002F1.73 m2.\n\nDecompensated liver disease or Child-Pugh class B\u002FC.\n\nALT or AST greater than 3 times the upper limit of normal at screening, unless judged clinically insignificant and approved by the investigator.\n\nKnown or suspected haemoglobinopathy that materially distorts HbA1c measurement or haemoglobin variant known to interfere with the central laboratory assay.\n\nBlood transfusion, significant blood loss greater than 250 mL, or erythropoiesis-stimulating agent therapy within 3 months before randomization.\n\nUntreated overt thyroid disease, or thyroid medication initiation or dose change within 3 months before randomization.\n\nUse of systemic corticosteroids within 4 weeks before randomization.\n\nUse of immunosuppressive medication or biologic\u002Fimmunomodulatory therapy within 5 half-lives before randomization.\n\nPregnancy or lactation; women of childbearing potential not willing to use effective contraception during the 24-week blinded period.\n\nSevere psychiatric illness or cognitive impairment that may compromise informed consent, safety, or adherence.\n\nActive eating disorder, defined operationally as a positive SCOFF screen with at least 2 affirmative responses at screening, or clinical diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder.\n\nHeavy alcohol use or active substance use disorder.\n\nCurrent very-low-calorie diet, ketogenic diet, medically supervised weight-loss diet, or other highly restrictive diet that excludes major food groups.\n\nCurrent cigarette smoking with intention to attempt cessation during the 24-week trial period; current users of nicotine-replacement or smoking-cessation pharmacotherapy initiated within 3 months before randomization.\n\nParticipation in another interventional clinical trial within 30 days before screening.\n\nKnown hypersensitivity or clinically significant intolerance to any component of the active product or placebo.\n\nInability or unwillingness to provide stool samples.\n\nAny condition that, in the investigator's opinion, would compromise participant safety or trial integrity.",{"count":602,"type":23},100,[121],"AIM-MET is a randomized clinical study testing whether a fixed microbiome-targeted nutritional product can improve blood sugar control in adults with type 2 diabetes when used in addition to usual stable diabetes treatment.\n\nThe study will compare the active nutritional product with a matching placebo over 24 weeks. The product was designed using artificial intelligence before the study began, but the same fixed formulation will be used for all participants assigned to the active group. Artificial intelligence will not be used during the study to make individual treatment decisions, adjust dosing, or personalize the product.\n\nThe main question is whether participants receiving the active product have a greater reduction in HbA1c, a standard marker of average blood sugar levels, from the start of the study to Week 24 compared with participants receiving placebo. The study will also evaluate early blood sugar changes, fasting glucose, body weight and waist measurements in participants with baseline BMI of at least 25.0 kg\u002Fm2, safety, hypoglycaemia events, patient-reported outcomes, and gut microbiome features.\n\nThis is a 100-participant proof-of-concept study intended to estimate the size of the treatment signal, safety, feasibility, and parameters needed for a future larger confirmatory trial.",[606,148],"Type 2 Diabetes",[608,609,610,611,184,612,613,614,615,616,617,599],"Type 2 diabetes","Type 2 diabetes mellitus","HbA1c","Glycemic response","Microbiome","Gut microbiome","Nutritional intervention","AI-guided formulation design","Artificial intelligence","Randomized controlled trial",{"date":619,"type":51},"2026-07-28",{"date":621,"type":51},"2026-06-01",{"date":623,"type":23},"2027-06-30",{"name":625,"class":58},"ENBIOSIS BIOTECHNOLOGIES",{"id":627,"slug":628,"hasResults":12,"nctId":629,"briefTitle":630,"officialTitle":631,"acronym":632,"eligibilityCriteria":633,"healthyVolunteers":12,"sex":18,"minAge":352,"maxAge":247,"enrollmentInfo":634,"targetDuration":4,"studyType":144,"phases":4,"briefSummary":636,"conditions":637,"keywords":4,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":469},"100633913","a-real-world-study-to-investigate-cardiovascular-risk-profile-among-newly-diagnosed-type-2-diabetes-mellitus-t2dm-participants-100633913","NCT07532863","A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants","A Retrospective Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus Participants in Southeast Asia","CRISTALSEA","Inclusion Criteria:\n\n* Aged greater than equal to (≥) 40 and less than (\\\u003C) 70 years\n* Male or female\n* Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023\n\nExclusion Criteria:\n\n* If any exclusion criterion is met, the participant will be excluded from the study.\n* T1DM or gestational diabetes\n* Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM\n* Pregnant women\n* With pre-existing atherosclerotic CVD including coronary heart disease, stroke, transient ischemic attack, or peripheral artery disease\n* Died within 12 months after first diagnosis of T2DM\n* Lost to follow-up i.e., no visit 12 months (± 3 months) after first diagnosis of T2DM",{"count":635,"type":23},400,"The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.",[29],{"date":619,"type":51},{"date":640,"type":51},"2026-03-13",{"date":642,"type":23},"2027-03-27",{"name":281,"class":58}]